Environmentally Friendly Plasma Coated Pressurised Metered Dose Inhalers



Mahmoud Ahmed Supervisor: Matthew Jones The University of Bath School of Pharmacy & Pharmacology



Background & Motivation

- □ Pressurised-metered dose inhalers (pMDIs) have been in medical use since the 1950s and have gone through many improvements and refining since their invention.
- D pMDIs are comprised of an aluminum canister, metering chamber, valve, and an actuator.
- □ Inside the canister is where the pharmaceutical formulation is held and consists of drug(s), excipients and propellant (Fig 1 & 2).





Phase 2: Surface-Drug Adhesion Measurement





- □ After the Montreal Protocol in 1987 when CFC propellants were banned. Huge push for alternative inhaler designs
- Development of internal surface treatments to reduce drug-canister adhesion and improve inhaler performance with the new generation of HFA propellants.
- □ Presspart has developed a new method of applying FCP (fluorocarbon polymer) on canister surfaces (Fig 3 & 3.1)
- □ Shown to improve FPD (fine particle dose) of inhalers and increase their useable lifespan.
- □ New method reduces environmental impact of the surface treatment process



Phase 3: Inhaler Performance Analysis

Utilising Next Generation Impactor coupled with High performance Liquid Chromatography to measure inhaler performance of our test canisters.



Objectives

- 1. Analysis of surface properties
 - 1. Surface energy
 - 2. Surface roughness
 - 3. Coating thickness
 - 4. Coating uniformity
- 2. Analysis of surface interactions with different drug candidates
 - 1. Surface-Drug adhesion properties
- 3. Analysis of inhaler performance
 - 1. Delivered dose from full to empty
 - 2. Inhaler performance when stored in different conditions and durations
- 4. Data analysis

Phase 1: Surface Properties Analysis

Contact Angle Measurement Using Water



SEM & AFM of Canister Surfaces







Next Generation Impactor set up and correspondence of the different stages to airway generations (Fig 10)

Responsible Innovation & Policy

- Close collaboration with Presspart who can review any data before publication
- Limited data in field due in part to pharmaceutical industry desire to protect intellectual property.
- □ Presspart have agreed to allow research public and encourage peer review
- We have already seen policy changes in the past due to the environmental impacts of CFC propellants
- □ Feasible that there will be a policy change for canister coating processes to produce less environmental waste in the future.

Challenges

- Current generation of HFAs are in the process of being phased out and replaced with a new generation
- □ The current roster of candidates include HFA 152a, 134a and 1234ze
- □ To ensure that this research remains applicable to future inhalers it will require the experiments to use some of these new propellant types. □ No way of ascertaining which propellant the industry will begin to shift to out of the current candidates. □ With close contact with Presspart and pharmaceutical insiders, we can more confidently choose appropriate propellants for use while carrying out phase 1 which does not involve the use of propellant filled canisters.
- H Н



References

- Hickey A, Rocha S. Pharmaceutical inhalation aerosol technology. 3rd ed.
- Labiris N, Dolovich M. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. British Journal of Clinical Pharmacology. 2003;56(6):588-599.
- AFM Principle How Does an Atomic Force Microscope Work? [Internet]. Oxford Instruments. 2022 [cited 23 April 2022]. Available from: https://afm.oxinst.com/outreach/how-does-an-afm-microscope-work
- Techniques and instrumentation in analytical chemistry. Amsterdam: Elsevier; 2012.
- Ganesan K, Ghosh S, Gopala Krishna N, Ilango S, Kamruddin M, Tyagi A. A comparative study on defect estimation using XPS and Raman spectroscopy in few layer nanographitic structures. Physical Chemistry Chemical Physics. 2016;18(32):22160-22167.